*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients
*
5 = High level of competence 4 = Moderately high level of competence 3 = Average level of competence 2 = Low level of competence 1 = No level of competence
54321
Implement therapeutic strategies when treating hematologic malignancies.
Provide an update of new molecular and immunological treatments being developed for these diseases.
Discuss and analyze the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.
Assessing your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.
*
Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, N/A= Not Applicable/Did Not Attend
54321Not Applicable
Optimizing Adoptive Cell Immunotherapeutics via GPS -Robert Sackstein, M.D., Ph.D.
Landscape of CAR T-cells in 2020 - Michel W. Sadelain, M.D., Ph.D.
Do CARs always have to be T Cells? - Katy Rezvani, M.D.
Management of CAR T-cell Toxicities - Samer A. Srour, MBChB, M.S.Allogeneic Transplants and Adoptive Immunotherapies
Landscape of Allogeneic Transplants in 2020 - Richard O’Reilly, M.D.
The Intestinal Microbiome in Allogeneic Transplantation - Kate Markey, MBBS, Ph.D.
Adoptive Immunotherapy With Donor-Derived T-Cells - Guenther Koehne, M.D., Ph.D.
Adoptive Immunotherapy With Third Party-Derived T-Cells - Susan E. Prockop, M.D.
*
*
*
*
*
*
*
*